替加环素对全球范围内收集的临床耐药监测亚群的抗菌活性检测（2011 年）。
Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
机构信息
JMI Laboratories, North Liberty, IA 52317, USA.
出版信息
Diagn Microbiol Infect Dis. 2013 Jun;76(2):217-21. doi: 10.1016/j.diagmicrobio.2013.02.009. Epub 2013 Mar 19.
Tigecycline was approved by the United States Food and Drug Administration in 2005 and has generally retained activity against resistant Gram-positive and Gram-negative organisms. We monitored the in vitro activity of this glycylcycline in 2011 for continued potency worldwide. A total of 22,005 unique clinical isolates were consecutively collected in North America (NA; 9232 isolates), Europe (EU; 6776), Latin America (LA; 2016), and Asia-Pacific region (APAC, 3981) and tested for susceptibility according to the reference broth microdilution method recommendations against tigecycline and numerous comparators. Oxacillin (methicillin) resistance rates in methicillin-resistant Staphylococcus aureus (MRSA) were 49.3%, 30.2%, 42.9%, and 37.8%, and vancomycin resistance rates in enterococci (VRE) were 27.0%, 11.3%, 6.3%, and 4.0% in NA, EU, LA, and APAC, respectively. All MRSA (2839) and >99% of VRE were susceptible to tigecycline. Among Escherichia coli, extended-spectrum β-lactamase (ESBL) rates varied from 12.6% in the NA to 57.4% in APAC, and only one strain was nonsusceptible to tigecycline. Tigecycline was active against ESBL phenotype (96.5-98.4% susceptible) and meropenem-nonsusceptible Klebsiella spp. (94.3-100.0% susceptible). Only 4 of 213 (1.9%) meropenem-nonsusceptible Klebsiella spp. were tigecycline-nonsusceptible, all with tigecycline minimum inhibitory concentration (MIC) of 4 μg/mL (intermediate). Among ceftazidime-nonsusceptible Enterobacter spp., 94.7-98.2% were susceptible to tigecycline. Meropenem-nonsusceptible Acinetobacter spp. varied from 51.2% in NA to 80.9% in APAC; and 83.8% (LA) to 93.9% (APAC) of strains were inhibited at a tigecycline MIC of ≤2 μg/mL. Tigecycline showed potent activity against Stenotrophomonas maltophilia (89.3-98.3% inhibited at ≤2 μg/mL). In summary, tigecycline has sustained potent activity and a broad-spectrum against clinically important bacteria causing infections worldwide, including multidrug-resistant organism subsets.
替加环素于 2005 年获得美国食品和药物管理局批准，通常对耐药革兰阳性和革兰阴性菌保持活性。我们监测了这种甘氨酰环素在 2011 年全球的持续效力。共连续收集了来自北美（NA；9232 株）、欧洲（EU；6776 株）、拉丁美洲（LA；2016 株）和亚太地区（APAC，3981 株）的 22005 株独特的临床分离株，根据参考肉汤微量稀释法建议，对替加环素和许多对照药物进行药敏试验。耐甲氧西林金黄色葡萄球菌（MRSA）的苯唑西林（甲氧西林）耐药率分别为 49.3%、30.2%、42.9%和 37.8%，肠球菌（VRE）的万古霉素耐药率分别为 27.0%、11.3%、6.3%和 4.0%在 NA、EU、LA 和 APAC 中。所有 MRSA（2839 株）和 >99%的 VRE 均对替加环素敏感。在大肠杆菌中，扩展谱β-内酰胺酶（ESBL）的发生率从 NA 的 12.6%到 APAC 的 57.4%不等，只有一株对替加环素不敏感。替加环素对 ESBL 表型（96.5-98.4%敏感）和耐美罗培南的肺炎克雷伯菌属（94.3-100.0%敏感）具有活性。在 213 株耐美罗培南的肺炎克雷伯菌属中，仅有 4 株（1.9%）对替加环素不敏感，所有菌株的替加环素最小抑菌浓度（MIC）均为 4μg/ml（中介）。在头孢他啶不敏感的肠杆菌科中，94.7-98.2%对替加环素敏感。耐美罗培南的不动杆菌属在 NA 中的比例为 51.2%，在 APAC 中的比例为 80.9%；而在 LA（83.8%）和 APAC（93.9%）的菌株中，替加环素 MIC≤2μg/ml 可抑制 83.8%-93.9%的菌株。替加环素对嗜麦芽窄食单胞菌具有强大的活性（89.3-98.3%在≤2μg/ml 时被抑制）。总之，替加环素对引起全球感染的重要临床细菌具有持续的强效广谱活性，包括多种耐药菌亚群。
Zotero 插件